P4-317 Gamma-secretase inhibitors: a critical evaluation of their potential therapeutic use in Alzheimer disease

2004 ◽  
Vol 25 ◽  
pp. S565
Author(s):  
Frédéric Checler
2006 ◽  
Vol 12 (33) ◽  
pp. 4313-4335 ◽  
Author(s):  
Chewki Ziani-Cherif ◽  
Bachir Mostefa-Kara ◽  
Fatima Brixi-Gormat

2006 ◽  
Vol 2 (4) ◽  
pp. 311-328 ◽  
Author(s):  
Speranta Avram ◽  
Adina Milac ◽  
Dan Mihailescu ◽  
Aurelia Dabu ◽  
Maria Flonta

2011 ◽  
Vol 71 ◽  
pp. e187
Author(s):  
Jun-ichi Satoh ◽  
Hiroko Tabunoki ◽  
Tsuyoshi Ishida ◽  
Kunimasa Arima

2020 ◽  
Vol 79 (6) ◽  
pp. 592-604 ◽  
Author(s):  
Derek H Oakley ◽  
Mirra Chung ◽  
Naomi Klickstein ◽  
Caitlin Commins ◽  
Bradley T Hyman ◽  
...  

Abstract Familial Alzheimer disease-causing mutations in Presenilin 1 (PSEN1) are generally thought to shift the processing of APP toward longer, more amyloidogenic Aβ fragments. However, certain PSEN1 mutations cause severe reduction in gamma secretase function when expressed in the homozygous state, thus challenging the amyloid hypothesis. We sought to evaluate the effects of one such mutation, PSEN1 L435F, in more physiologic conditions and genetic contexts by using human induced pluripotent stem cell (iPSC)-derived neurons from an individual with familial AD (fAD) linked to the PSEN1 L435F mutation, and compared the biochemical phenotype of the iPS-derived neurons with brain tissue obtained at autopsy from the same patient. Our results demonstrate that in the endogenous heterozygous state, the PSEN1 L435F mutation causes a large increase in soluble Aβ43 but does not change the overall levels of soluble Aβ40 or Aβ42 when compared with control iPSC-neurons. Increased pathologically phosphorylated tau species were also observed in PSEN1-mutant iPSC-neurons. Concordant changes in Aβ species were present in autopsy brain tissue from the same patient. Finally, the feasibility of using Aβ43 immunohistochemistry of brain tissue to identify fAD cases was evaluated in a limited autopsy case series with the finding that strong Aβ43 staining occurred only in fAD cases.


2013 ◽  
Vol 24 ◽  
pp. e37
Author(s):  
Zdena Kristofikova ◽  
Jana Sirova ◽  
Jan Ricny ◽  
Jan Korabecny ◽  
Kamil Kuca ◽  
...  

2018 ◽  
Author(s):  
Ammad Aslam Khan ◽  
Bushra Mirza ◽  
Hashim Ali Raja

AbstractPresenilin proteins are type II transmembrane proteins. They make the catalytic component of Gamma secretase, a multiportion transmembrane protease. Amyloid protein, Notch and beta catenin are among more than 90 substrates of Presenilins. Mutations in Presenilins lead to defects in proteolytic cleavage of its substrate resulting in some of the most devastating pathological conditions including Alzheimer disease (AD), developmental disorders and cancer. In addition to catalytic roles, Presenilin protein is also shown to be involved in many non-catalytic roles i.e. calcium homeostasis, regulation of autophagy and protein trafficking etc. These proteolytic proteins are highly conserved, present in almost all the major eukaryotic groups. Studies on wide variety of organisms ranging from human to unicellular dictyostelium have shown the important catalytic and non-catalytic roles of Presenilins. In the current research project, we aimed to elucidate the phylogenetic history of Presenilins. We showed that Presenilins are the most ancient of the Gamma secretase proteins and might have their origin in last common eukaryotic ancestor (LCEA). We also demonstrated that these proteins have been evolving under strong purifying selection. Through evolutionary trace analysis, we showed that Presenilin protein sites which undergoes mutations in Familial Alzheimer Disease are highly conserved in metazoans. Finally, we discussed the evolutionary, physiological and pathological implication of our findings and proposed that evolutionary profile of Presenilins supports the loss of function hypothesis of AD pathogenesis.


Sign in / Sign up

Export Citation Format

Share Document